Clinical Trial Update: Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5-PBGD for the Treatment of Acute Intermittent Porphyria [Phase 1]

View source ↗

Summary

A Phase I gene therapy trial using the rAAV2/5-PBGD vector for acute intermittent porphyria has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intermittent Porphyria

Drugs mentioned

• rAAV2/5-PBGD

Snippet

Sponsor: Digna Biotech S.L. | Conditions: Acute Intermittent Porphyria | Phase 1 | Status: COMPLETED